Hexagon Capital Partners LLC Sells 39 Shares of Danaher Co. (NYSE:DHR)

Hexagon Capital Partners LLC cut its holdings in shares of Danaher Co. (NYSE:DHR) by 3.4% during the third quarter, Holdings Channel reports. The fund owned 1,114 shares of the conglomerate’s stock after selling 39 shares during the quarter. Hexagon Capital Partners LLC’s holdings in Danaher were worth $310,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Tsfg LLC raised its holdings in Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. bought a new stake in Danaher during the second quarter worth about $25,000. nVerses Capital LLC bought a new stake in Danaher during the second quarter worth about $25,000. Redmont Wealth Advisors LLC bought a new position in shares of Danaher in the first quarter worth about $30,000. Finally, Richardson Financial Services Inc. bought a new position in shares of Danaher in the fourth quarter worth about $42,000. 79.05% of the stock is owned by institutional investors.

Danaher Price Performance

Shares of DHR stock opened at $266.45 on Friday. The stock has a market cap of $197.36 billion, a price-to-earnings ratio of 45.16, a PEG ratio of 4.55 and a beta of 0.83. The business’s fifty day moving average is $270.73 and its 200 day moving average is $258.92. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the prior year, the firm posted $2.05 earnings per share. The company’s quarterly revenue was down 2.9% on a year-over-year basis. Research analysts expect that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s payout ratio is currently 18.31%.

Insider Activity

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock valued at $11,042,433 over the last ninety days. 11.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Stephens initiated coverage on shares of Danaher in a report on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 target price for the company. Evercore ISI raised their price objective on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price objective on shares of Danaher in a report on Friday, September 6th. Barclays raised their price objective on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. Finally, StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Seven research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $282.12.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.